Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial
Michael C. Kreißl(University Hospital Magdeburg), Martin Schlumberger(Institut Gustave Roussy), Raffaella Colzani, R. J. Weiss(University of Georgia), Rossella Elisei(University of Pisa), Lars Bastholt(Odense University Hospital), Ole Hauch, Robert I. Haddad(Georgetown University), Barbara Jarząb(The Maria Sklodowska-Curie National Research Institute of Oncology), Meredith C. Foster(Tufts University), Bruce Robinson(University of Michigan)
Cited by 61
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
|New England Journal of Medicine|2012|863